^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    GENE:

    IFNL2 (Interferon Lambda 2)

    i
    Other names: IFNL2, Interferon Lambda 2, IL-28A, IL28A, Interleukin 28A (Interferon, Lambda 2), Interferon Lambda-2, Cytokine Zcyto20, Interleukin-28A, IFN-Lambda-2, Interleukin 28A, ZCYTO20, IFNL2a, IFNL3a
    Associations

    News

    Trials
    9ms
    IFN-λ: Unleashing Its Potential in Disease Therapies From Acute Inflammation Regulation to Cancer Immunotherapy. (PubMed, Immunology)
    However, the precise mechanisms by which IFN-λ influence immune modulation and disease progression remain an area of active investigation. This review aims to provide an overview of the structure, function and signalling pathways of IFN-λ, exploring their role in immune-related diseases and discussing potential avenues for therapeutic intervention.
    Review • Journal • IO biomarker
    |
    IL10 (Interleukin 10) • IFNL2 (Interferon Lambda 2) • IFNL3 (Interferon Lambda 3)
    over1year
    STRONG: Investigating the Combined Effects of Protein, Blueberries, and Exercise on Cardiovascular Health and Frailty in Older Nova Scotians (clinicaltrials.gov)
    P=N/A, N=240, Not yet recruiting, Nova Scotia Health Authority
    New trial
    |
    TNFRSF8 (TNF Receptor Superfamily Member 8) • IFNG (Interferon, gamma) • IL2 (Interleukin 2) • IL10 (Interleukin 10) • MMP2 (Matrix metallopeptidase 2) • TNFRSF1A (TNF Receptor Superfamily Member 1A) • IL32 (Interleukin 32) • TNFSF13B (TNF Superfamily Member 13b) • IFNA1 (Interferon Alpha 1) • IL22 (Interleukin 22) • MMP1 (Matrix metallopeptidase 1) • TSLP (Thymic Stromal Lymphopoietin) • IFNB1 (Interferon Beta 1) • IFNL1 (Interferon Lambda 1) • IFNL2 (Interferon Lambda 2) • MMP3 (Matrix metallopeptidase 3) • TNFSF13 (TNF Superfamily Member 13) • TNFSF14 (TNF Superfamily Member 14)
    over1year
    Copy number variation and clinical response to chemotherapy and bevacizumab in the Czech metastatic colorectal cancer patients. (PubMed, Klin Onkol)
    In the pilot study, we found promising copy number variation biomarkers of bevacizumab response in FFPE samples of mCRC patients. The validation phase should be focused especially on the genes associated with angiogenesis (AGRN, MAPK8, ARHGAP22, LGALS13, LGALS4, ZFP36, and MYC), tumorigenesis (DVL1), and tumor proliferation (IFNL1, IFNL2, IFNL3, MAP3K10, and MAP4K1).
    Journal • Metastases
    |
    LGALS1 (Galectin 1) • MAP3K10 (Mitogen-Activated Protein Kinase Kinase Kinase 10) • LGALS4 (Galectin 4) • AGRN (Agrin) • DVL1 (Dishevelled Segment Polarity Protein 1) • IFNL1 (Interferon Lambda 1) • IFNL2 (Interferon Lambda 2) • IFNL3 (Interferon Lambda 3) • MAPK8 (Mitogen-activated protein kinase 8) • ZFP36 (ZFP36 Ring Finger Protein)
    |
    Avastin (bevacizumab)
    over1year
    BEAUTY: Abemaciclib in Treating Patients With Surgically Resectable, Chemotherapy Resistant, Triple Negative Breast Cancer (clinicaltrials.gov)
    P2, N=200, Recruiting, Mayo Clinic | Trial completion date: Jul 2024 --> Jul 2025 | Trial primary completion date: Jul 2024 --> Jul 2025
    Trial completion date • Trial primary completion date
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor) • CD20 (Membrane Spanning 4-Domains A1) • JAK2 (Janus kinase 2) • CD8 (cluster of differentiation 8) • CDH1 (Cadherin 1) • CCR4 (C-C Motif Chemokine Receptor 4) • IL2RA (Interleukin 2 receptor, alpha) • PTPRC (Protein Tyrosine Phosphatase Receptor Type C) • NCAM1 (Neural cell adhesion molecule 1) • CCR5 (C-C Motif Chemokine Receptor 5) • CCR7 (Chemokine (C-C motif) receptor 7) • CD14 (CD14 Molecule) • CD27 (CD27 Molecule) • GZMB (Granzyme B) • HLA-B (Major Histocompatibility Complex, Class I, B) • NLRC5 (NLR Family CARD Domain Containing 5) • FOXP3 (Forkhead Box P3) • IKZF2 (IKAROS family zinc finger 2) • IL3RA (Interleukin 3 Receptor Subunit Alpha) • STAT1 (Signal Transducer And Activator Of Transcription 1) • CXCR3 (C-X-C Motif Chemokine Receptor 3) • CXCR5 (C-X-C Motif Chemokine Receptor 5) • ITGAX (Integrin Subunit Alpha X) • PRF1 (Perforin 1) • SNAI2 (Snail Family Transcriptional Repressor 2) • TAP1 (Transporter 1) • CCR6 (C-C Motif Chemokine Receptor 6) • CEACAM8 (CEA Cell Adhesion Molecule 8) • DDX58 (DExD/H-Box Helicase 58) • HLA-C (Major Histocompatibility Complex, Class I, C) • IFNL1 (Interferon Lambda 1) • IFNL2 (Interferon Lambda 2) • IFNL3 (Interferon Lambda 3) • ITGB1 (Integrin Subunit Beta 1) • KLRB1 (Killer Cell Lectin Like Receptor B1)
    |
    Verzenio (abemaciclib)
    over1year
    IL-28A/IL-10Rβ axis promotes angiogenesis via eNOS/AKT signaling and AP-1/NF-κB/MMP-2 network by regulating HSP70-1 expression. (PubMed, J Adv Res)
    HSP70-1 drives the progression of angiogenesis by the IL-28A/IL-10Rβ axis via eNOS/AKT signaling and the AP-1/NF-κB/MMP-2 network.
    Journal
    |
    MMP2 (Matrix metallopeptidase 2) • NOS3 (Nitric oxide synthase 3) • IFNL2 (Interferon Lambda 2)
    almost2years
    Membrane Proteome-Wide Screening of Autoantibodies in CIDP Using Human Cell Microarray Technology. (PubMed, Neurol Neuroimmunol Neuroinflamm)
    Our work demonstrates the utility of human cell microarray technology to detect known and discover unknown autoantibodies in human serum samples. Despite potential CIDP-associated autoantibodies (anti-LIF and anti-IFNL3) being identified, their clinical and pathogenic relevance needs to be elucidated in bigger cohorts.
    Journal
    |
    EPHA7 (EPH Receptor A7) • CNTN1 (Contactin 1) • IFNL1 (Interferon Lambda 1) • IFNL2 (Interferon Lambda 2) • IFNL3 (Interferon Lambda 3) • LIF (LIF Interleukin 6 Family Cytokine)
    2years
    Interleukin 28A aggravates Con A-induced acute liver injury by promoting the recruitment of M1 macrophages. (PubMed, FASEB J)
    In summary, IL-28A deletion plays an important protective role in the Con A-induced acute liver injury model and IL-28A deficiency inhibits the activation of M1 macrophages by inhibiting the NF-κB, MAPK, and IRF signaling pathways. These results provide a potential new target for the treatment of immune-related hepatic injury.
    Journal
    |
    IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha) • IL10 (Interleukin 10) • IL1B (Interleukin 1, beta) • IFNL2 (Interferon Lambda 2)
    over2years
    Distinct Subtypes of Chemotherapy-Resistant Systemic ALK-Positive Anaplastic Large Cell Lymphoma Demonstrate Long-Term Complete Remissions to Imatinib (ASH 2023)
    ConclusionPDGFRA/B expression in tumour cells of therapy-resistant ALK-positive ALCL patients can discriminate genetically and functionally distinct lymphoma subgroups that are directly related to long-term treatment response to kinase inhibitor imatinib. Our data suggests that significant imatinib responses may be achieved in more than 80% of chemotherapy-resistant ALK+ ALCL cases.
    Clinical
    |
    ALK (Anaplastic lymphoma kinase) • KIT (KIT proto-oncogene, receptor tyrosine kinase) • NPM1 (Nucleophosmin 1) • PDGFRA (Platelet Derived Growth Factor Receptor Alpha) • TNFA (Tumor Necrosis Factor-Alpha) • IFNL2 (Interferon Lambda 2)
    |
    TP53 mutation • ALK positive • PDGFRA mutation • NPM1 expression
    |
    imatinib
    over2years
    NUTOBREST: Nutritional Intervention-induced Weight Loss During the Oncological Treatment of Obesity-related Breast Cancer (clinicaltrials.gov)
    P=N/A, N=220, Not yet recruiting, Hospital Clinico Universitario de Santiago
    New trial
    |
    TNFRSF8 (TNF Receptor Superfamily Member 8) • TNFA (Tumor Necrosis Factor-Alpha) • CD163 (CD163 Molecule) • IL6R (Interleukin 6 receptor) • IL22 (Interleukin 22) • TSLP (Thymic Stromal Lymphopoietin) • IFNL1 (Interferon Lambda 1) • IFNL2 (Interferon Lambda 2) • MMP3 (Matrix metallopeptidase 3)
    3years
    Common Microbial Genital Infections and Their Impact on the Innate Immune Response to HPV in Cervical Cells. (PubMed, Pathogens)
    TLR9-increased expression was associated with HPV persistence in previous studies; hence, bacterial coinfections may enhance this risk. Prospective measurements of type III IFNs and IFNLR1 are warranted to evaluate whether this response may act as a double-edged sword in infected epithelia.
    Journal • IO biomarker
    |
    CCL20 (C-C Motif Chemokine Ligand 20) • TLR9 (Toll Like Receptor 9) • TLR7 (Toll Like Receptor 7) • IFNL1 (Interferon Lambda 1) • IFNL2 (Interferon Lambda 2)
    |
    TLR9 expression
    over3years
    NFIC1 suppresses migration and invasion of breast cancer cells through interferon-mediated Jak-STAT pathway. (PubMed, Arch Biochem Biophys)
    Treatment with Jak-STAT pathway inhibitors, Filgotinib or Ruxolitinib, reversed the suppressive effects of NFIC1 overexpression on migration and invasion of MCF-7 cells. In addition, we found that MX1 and MX2, two target genes of Jak-STAT pathway, mediated the migration and invasion of MCF-7 cells. These results demonstrated that NFIC1 inhibited the migration and invasion in MCF-7 cells through interferon-mediated activation of Jak-STAT pathway, indicating that Jak-STAT pathway might be a potential therapeutic target for preventing breast cancer metastasis.
    Journal
    |
    IFNB1 (Interferon Beta 1) • IFNL1 (Interferon Lambda 1) • IFNL2 (Interferon Lambda 2) • IFNL3 (Interferon Lambda 3) • MX1 (MX Dynamin Like GTPase 1) • NFIC (Nuclear Factor I C)
    |
    Jakafi (ruxolitinib)